Skip to main content

Table 3 Differences between baseline and follow-up on secondary outcome measures (n = 107 complete cases)

From: Preliminary effects of a regional approached multidisciplinary educational program on healthcare utilization in patients with hip or knee osteoarthritis: an observational study

 

Baseline

Follow-up

p-value

BMI (kg/m2), mean (SD)

27.1 (4.4)

26.7 (4.1)

0.16b *

WOMAC pain (range 0–100), mean (SD)

66.8 (21.4)

69.7 (20.1)

0.13b

WOMAC functioning (range 0–100), mean (SD)

68.3 (19.6)

67.8 (21.2)

0.78b

Medication use, n (%)

   

 Paracetamol

65 (61.9)

62 (59.1)

0.65a

 NSAIDS

33 (32.4)

25 (24.5)

0.08a

 Other

14 (13.1)

17 (15.9)

0.45a

SQUASH Total activity (min/week), mean (SD)

2128.9 (1023.1)

2349.2 (1246.8)

0.07b

IPQ Illness perceptions (range 0–100), mean (SD)

41.3 (10.5)

39.5 (10.5)

0.02b *

GSES Self-efficacy (10–40), mean (SD)

32.1 (5.9)

32.2 (5.6)

0.85b

PAM-13, patient activation (13–52), mean (SD)

39.3 (0.5)

40.1 (0.5)

0.15b

Knowledge on OA (0–22), mean (SD)

10.5 (3.7)

12.9 (3.1)

0.00b *

  1. aExact McNemar significance probability
  2. bPaired sample t-test, two-sided
  3. *Significant for p-value ≤0.05